enGene (NASDAQ:ENGN – Get Free Report) and iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
Volatility & Risk
enGene has a beta of -0.65, meaning that its stock price is 165% less volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500.
Institutional and Insider Ownership
64.2% of enGene shares are held by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are held by institutional investors. 13.7% of enGene shares are held by company insiders. Comparatively, 12.5% of iTeos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| enGene | N/A | -16.69% | -14.27% |
| iTeos Therapeutics | N/A | -20.11% | -17.50% |
Earnings & Valuation
This table compares enGene and iTeos Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| enGene | N/A | N/A | -$55.14 million | ($0.58) | -10.76 |
| iTeos Therapeutics | $12.60 million | 21.48 | -$112.64 million | ($3.15) | -2.35 |
enGene has higher earnings, but lower revenue than iTeos Therapeutics. enGene is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and price targets for enGene and iTeos Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| enGene | 0 | 1 | 8 | 1 | 3.00 |
| iTeos Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
enGene presently has a consensus target price of $25.89, indicating a potential upside of 314.69%. iTeos Therapeutics has a consensus target price of $22.25, indicating a potential upside of 200.27%. Given enGene’s higher probable upside, analysts plainly believe enGene is more favorable than iTeos Therapeutics.
Summary
enGene beats iTeos Therapeutics on 8 of the 12 factors compared between the two stocks.
About enGene
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
About iTeos Therapeutics
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.
